Cytek Biosciences, Inc.
NasdaqGS:CTKB 株式レポート
Cytek Biosciences マネジメント Cytek Biosciencesの CEO はWenbin Jiangで、 Dec2014年に任命され、 の在任期間は 9.92年です。 の年間総報酬は$ 4.94Mで、 11.7%給与と88.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の4%を直接所有しており、その価値は$ 36.30M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と2.9年です。
主要情報 CEO給与比率 11.7% CEO在任期間 9.9yrs CEOの所有権 4.0% 経営陣の平均在職期間 3.6yrs 取締役会の平均在任期間 2.9yrs
経営陣の近況
Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024 Sep 12
Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024 Apr 28 Cytek Biosciences, Inc. Announces CFO Changes
CTO & Director notifies of intention to sell stock Oct 22
President notifies of intention to sell stock Sep 10
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services Aug 29
すべての更新を表示
Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs System Nov 08
Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump Nov 07
New minor risk - Share price stability Nov 06
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 06
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 06
Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 30
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story Sep 13
Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024 Sep 12
Price target decreased by 8.4% to US$8.70 Aug 16
Consensus EPS estimates fall by 90% Aug 15
Consensus EPS estimates fall by 52% Aug 13
An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued Aug 09
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 07 Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024 Aug 07
Cytek Biosciences, Inc. Automates Panel Design with New Intelligent Algorithm
Consensus EPS estimates fall by 15% Jul 23
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly? Jul 12 Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. Jun 08
Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk Jun 04
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024 May 10
Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024 May 01
Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader Mar 20 Cytek Biosciences, Inc. Announces CFO Changes Cytek Biosciences, Inc. announced delayed annual 10-K filing Mar 03
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 Mar 01
Full year 2023 earnings released Feb 29
Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry Dec 21
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 15 Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 14
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Nov 08
CTO & Director notifies of intention to sell stock Oct 22
Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 20
Price target decreased by 14% to US$12.25 Oct 18
President notifies of intention to sell stock Sep 10
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services Aug 29
CTO & Director notifies of intention to sell stock Aug 24
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 23
CTO & Director notifies of intention to sell stock Jun 25
President notifies of intention to sell stock Jun 11
Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. May 20
President notifies of intention to sell stock May 12
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 11
Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023 May 10
CTO & Director notifies of intention to sell stock Apr 23
Consensus EPS estimates increase by 22% Apr 19
Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals Mar 08
Price target decreased by 9.1% to US$15.00 Mar 07
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 02
Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million. Feb 14
President notifies of intention to sell stock Feb 12
Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
CTO & Director notifies of intention to sell stock Jan 23
President notifies of intention to sell stock Dec 11
Chief Financial Officer notifies of intention to sell stock Dec 02
CTO & Director notifies of intention to sell stock Nov 25
Lead Independent Director exercised options and sold US$229k worth of stock Nov 17
Cytek Biosciences, Inc. Introduces Cytek Cloud Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022 Nov 10
Cytek Biosciences, Inc. Names Chris Williams Chief Operating Officer Nov 01
Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
President notifies of intention to sell stock Sep 11
CTO & Director notifies of intention to sell stock Aug 25
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 12
Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 11
Chief Financial Officer notifies of intention to sell stock Aug 05
Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments Jul 27
Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Index Jun 26
Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022 Jun 24
Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I Director Jun 07
CTO & Director notifies of intention to sell stock May 23
President notifies of intention to sell stock May 13
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022 May 12
Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022 Apr 15
Consensus forecasts updated Apr 14
Checking In On Cytek Biosciences Mar 23
President exercised options and sold US$248k worth of stock Mar 10
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 01
Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Feb 24
CTO & Director notifies of intention to sell stock Feb 14
Cytek Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 12
Cytek Biosciences, Inc. has completed an IPO in the amount of $247.598795 million. Jul 24
CEO報酬分析 Cytek Biosciences の収益と比較して、Wenbin Jiang の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a -US$10m
Jun 30 2024 n/a n/a -US$18m
Mar 31 2024 n/a n/a -US$12m
Dec 31 2023 US$5m US$578k -US$12m
Sep 30 2023 n/a n/a -US$14m
Jun 30 2023 n/a n/a -US$6m
Mar 31 2023 n/a n/a -US$2m
Dec 31 2022 US$4m US$524k US$2m
Sep 30 2022 n/a n/a -US$901k
Jun 30 2022 n/a n/a -US$3m
Mar 31 2022 n/a n/a -US$2m
Dec 31 2021 US$5m US$375k US$52k
Sep 30 2021 n/a n/a US$575k
Jun 30 2021 n/a n/a US$2m
Mar 31 2021 n/a n/a US$4m
Dec 31 2020 US$422k US$241k US$3m
報酬と市場: Wenbinの 総報酬 ($USD 4.94M ) は、 US市場 ($USD 3.18M ) の同規模の企業の平均を上回っています。
報酬と収益: Wenbinの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者 Dr. Wenbin Jiang, Ph D., is co-founder, Chairman and President of Cytek Biosciences, Inc and has been its Chief Executive Officer and Director since December 2014. Dr. Jiang is a seasoned entrepreneur and ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 President 9.9yrs US$4.94m 4% $ 36.3m CTO & Director 9.8yrs US$3.07m 4.66% $ 42.3m Chief Legal Officer & Corporate Secretary 3.8yrs US$1.86m 0.042% $ 379.6k Senior Vice President of Business & Corporate Development 3.6yrs US$1.43m 0.044% $ 400.1k Head of Corporate Development Analytics less than a year US$1.79m 0.076% $ 686.2k Chief Financial Officer less than a year データなし データなし Senior Vice President of Global Sales & Services 1.3yrs データなし 0.0082% $ 74.5k
もっと見る
経験豊富な経営陣: CTKBの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 President 9.9yrs US$4.94m 4% $ 36.3m CTO & Director 9.8yrs US$3.07m 4.66% $ 42.3m Independent Director 2.4yrs US$215.67k 0% $ 0 Independent Director 2.4yrs US$217.50k 0% $ 0 Lead Independent Director 6.2yrs US$260.00k 0.021% $ 190.1k Independent Director less than a year データなし 0.0011% $ 10.2k Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Independent Director 2.9yrs US$215.00k 0% $ 0
もっと見る
経験豊富なボード: CTKBの 取締役会 は 経験豊富 ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
